• 1
    Lip GYH, Hart RG, Conway DSG. ABC of antithrombotic therapy: antithrombotic therapy for atrial fibrillation. BMJ 2002; 325: 10225.
  • 2
    Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation 2006; 114: e257354.
  • 3
    Gage BF, Van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BSP, Petersen P. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004; 110: 228792.
  • 4
    Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA 2001; 285: 286470.
  • 5
    Szucs TD, Bramkamp M. Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review. J Thromb Haemostasis 2006; 4: 11805.
  • 6
    Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994–1998: analysis of data from the general practice research database. Heart 2001; 86: 2848.
  • 7
    Ruigómez A, Johansson S, Wallander M-A, Rodriguez LA. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol 2002; 55: 35863.
  • 8
    Partington SL, Abid S, Teo K, Oczkowski W, O’Donnell MJ. Pre-admission warfarin use in patients with acute ischemic stroke and atrial fibrillation: the appropriate use and barriers to oral anticoagulant therapy. Thromb Res 2007; 120: 6639.
  • 9
    Simpson CR, Wilson C, Hannaford PC, Williams D. Evidence for age and sex differences in the secondary prevention of stroke in Scottish primary care. Stroke 2005; 36: 17715.
  • 10
    Somerfield J, Barber PA, Anderson NE, Kumar A, Spriggs D, Charleston A, Bennett P, Baker Y, Ross L. Not all patients with atrial fibrillation-associated ischemic stroke can be started on anticoagulant therapy. Stroke 2006; 37: 121720.
  • 11
    Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol 2003; 41: 5661.
  • 12
    Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998; 97: 12313.
  • 13
    Tapson VF, Hyers TM, Waldo AL, Ballard DJ, Becker RC, Caprini JA, Khetan R, Wittkowsky AK, Colgan KJ, Shillington AC, NABOR (National Anticoagulation Benchmark and Outcomes Report) Steering Committee. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med 2005; 165: 145864.
  • 14
    Waldo AL, Becker RC, Tapson VF, Colgan KJ, NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 2005; 46: 172936.
  • 15
    Dinh T, Nieuwlaat R, Tieleman RG, Büller HR, Van Charante NA, Prins MH, Crijns HJ. Antithrombotic drug prescription in atrial fibrillation and its rationale among general practitioners, internists and cardiologists in The Netherlands – the EXAMINE-AF study. A questionnaire survey. Int J Clin Pract 2007; 61: 2431.
  • 16
    FALSTAF Study Group, Leizorovicz A, Cohen A, Guenoun M, Mismetti P, Weisslinger N. Influence of age on the prescription of vitamin K antagonists in outpatients with permanent atrial fibrillation in France. Pharmacoepidemiol Drug Saf 2007; 16: 328.
  • 17
    Friberg L, Hammar N, Ringh M, Pettersson H, Rosenqvist M. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study) Eur Heart J 2006; 27: 195464.
  • 18
    Glazer NL, Dublin S, Smith NL, French B, Jackson LA, Hrachovec JB, Siscovick DS, Psaty BM, Heckbert SR. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med 2007; 167: 24652.
  • 19
    Lamassa M, Di Carlo A, Pracucci G, Basile AM, Trefoloni G, Vanni P, Spolveri S, Baruffi MC, Landini G, Ghetti A, Wolfe CD, Inzitari D. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001; 32: 3928.
  • 20
    Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, Cobbe S, Breithardt G, Le Heuzey JY, Prins MH, Lévy S, Crijns HJ, European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 242234.
  • 21
    DeWilde S, Carey IM, Emmas C, Richards N, Cook DG. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 2006; 92: 106470.
  • 22
    Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997; 350: 10979.
  • 23
    Rietbrock S, Heeley E, Plumb J, Van Staa TP. Chronic atrial fibrillation: incidence, prevalence and prediction of stroke using the CHADS2 risk stratification scheme. Am Heart J 2008; 156: 5764.
  • 24
    Gross CP, Vogel EW, Dhond AJ, Marple CB, Edwards RA, Hauch O, Demers EA, Ezekowitz M. Factors influencing physicians’ reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. Clin Ther 2003; 25: 175064.
  • 25
    Kakar P, Lane D, Lip GY. Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation. Chest 2006; 130: 12968.
  • 26
    Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095106.
  • 27
    Feldstein AC, Smith DH, Perrin N, Yang X, Simon SR, Krall M, Sittig DF, Ditmer D, Platt R, Soumerai SB. Reducing warfarin medication interactions: an interrupted time series evaluation. Arch Intern Med 2006; 166: 100915.
  • 28
    Van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129: 115566.